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Purpose
Triamcinolone acetonide (TAA) is considered a first-line drug by itself or as a
combined treatment of several intraocular diseases such as macular edema, retinal
vein thrombosis, uveitis and age-related macular degeneration. The development of
TAA dosage forms is limited due to its poor solubility in water and physiologically
acceptable solvents. Lipid nanocapsules (LNCs) are biocompatible systems that
allow loading both hydrophobic and hydrophilic drugs. LNCs present a versatile
composition and application suitable for different routes of administration. The aim
of this work was to develop and characterize a novel lipid LNCs formulation
containing TAA as drug delivery system.
Methods
LNCs were prepared in triplicate using an optimized phase inversion-based method
described by Heurtault et al., 2002. Due to the poor solubility of TAA in the oily
phase of the original formulation, two co-surfactants (captex® 500p -Glyceryl
triacetate and oleic acid) in three proportions (20, 30 and 50%) were tested. The
average particle size (APS), polydispersity index (PI), zeta potential (ZP) and
entrapment efficacy (EE) were measured.
Results
Acceptable results were obtained with a 20% of both co-surfactants. LNCs with
captex® 500p leads to about (40±1) nm size nanoparticles with a narrow size
distribution (PI less than 0.2), a negative ZP (-1.2±0.7) mV and EE (85.8±0.8) %
while LNCs with oleic acid showed an APS of (35.9± 0.6) nm and a PI below 0.1
with a negative ZP (-3.6±0.6) mV and EE (87±2) %. Moreover, both systems were
stable for two months.
Conclusions
LNCs allow encapsulation of TAA and their properties remain constant over long
periods of time. Thus, LNCs are promising systems than may be a potential
strategy to improve efficacy and decrease side effects of this drug so used in the
treatment of intraocular diseases.
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